Short Interest in Aptinyx Inc. (NASDAQ:APTX) Declines By 19.6%

Aptinyx Inc. (NASDAQ:APTXGet Rating) was the recipient of a large decline in short interest in April. As of April 30th, there was short interest totalling 1,270,000 shares, a decline of 19.6% from the April 15th total of 1,580,000 shares. Approximately 2.8% of the company’s shares are sold short. Based on an average daily volume of 397,500 shares, the short-interest ratio is presently 3.2 days.

Hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its position in Aptinyx by 244.5% during the 2nd quarter. Royal Bank of Canada now owns 9,288 shares of the company’s stock worth $26,000 after acquiring an additional 6,592 shares during the last quarter. Lindbrook Capital LLC acquired a new position in Aptinyx during the 4th quarter worth $53,000. Commonwealth Equity Services LLC acquired a new position in Aptinyx during the 4th quarter worth $29,000. Dimensional Fund Advisors LP lifted its position in Aptinyx by 5.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 123,937 shares of the company’s stock worth $331,000 after acquiring an additional 6,133 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in Aptinyx during the 4th quarter worth $54,000. 55.97% of the stock is owned by institutional investors and hedge funds.

APTX stock opened at $0.63 on Tuesday. The company has a current ratio of 20.18, a quick ratio of 20.18 and a debt-to-equity ratio of 0.15. Aptinyx has a 1 year low of $0.57 and a 1 year high of $4.73. The company has a fifty day simple moving average of $1.74 and a 200 day simple moving average of $2.42. The firm has a market cap of $42.83 million, a PE ratio of -0.54 and a beta of 1.46.

Aptinyx (NASDAQ:APTXGet Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.02. During the same quarter last year, the business posted ($0.22) earnings per share. As a group, analysts forecast that Aptinyx will post -1.1 EPS for the current fiscal year.

APTX has been the topic of several research analyst reports. HC Wainwright lowered their price target on shares of Aptinyx from $8.00 to $2.00 and set a “buy” rating on the stock in a report on Thursday, April 14th. SVB Leerink lowered their price target on shares of Aptinyx from $10.00 to $4.00 and set an “outperform” rating on the stock in a report on Thursday, April 21st. Cantor Fitzgerald lowered their price target on shares of Aptinyx from $11.00 to $5.00 and set an “overweight” rating on the stock in a report on Friday, April 8th. William Blair cut shares of Aptinyx from an “outperform” rating to a “market perform” rating in a report on Thursday, April 7th. Finally, Zacks Investment Research cut shares of Aptinyx from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $3.88.

About Aptinyx (Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

Featured Stories

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.